Journal ArticleDOI
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience.
Matteo Bassetti,Nadia Castaldo,Anna Maria Cattelan,Cristina Mussini,Elda Righi,Carlo Tascini,Francesco Menichetti,Claudio Maria Mastroianni,Mario Tumbarello,Paolo Grossi,S. Artioli,Novella Carannante,Ludovica Cipriani,Davide Coletto,Alessandro Russo,Margherita Digaetano,Angela Raffaella Losito,Maddalena Peghin,Alessandro Capone,Stefano Nicolè,Antonio Vena +20 more
Reads0
Chats0
TLDR
This study describes the largest clinical experience using ceftolozane/tazobactam (C/T) for different Pseudomonas aeruginosa infections in Italy and demonstrates a favourable safety and tolerability profile regardless of the infection type.About:
This article is published in International Journal of Antimicrobial Agents.The article was published on 2019-04-01. It has received 113 citations till now. The article focuses on the topics: Ceftolozane & Tazobactam.read more
Citations
More filters
Journal ArticleDOI
Antimicrobial resistance in ESKAPE pathogens
David M. P. De Oliveira,Brian M. Forde,Timothy J. Kidd,Patrick N A Harris,Mark A. Schembri,Scott A. Beatson,David L. Paterson,Mark J. Walker +7 more
TL;DR: The acquisition of antimicrobial resistance genes by ESKAPE pathogens has reduced the treatment options for serious infections, increased the burden of disease, and increased death rates due to treatment failure and requires a coordinated global response for antim antibiotic resistance surveillance.
Journal ArticleDOI
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan Pablo Horcajada,Milagro Montero,Antonio Oliver,Luisa Sorlí,Sonia Luque,Silvia Gómez-Zorrilla,Natividad Benito,Santiago Grau +7 more
TL;DR: This article reviews the mechanisms of resistance, epidemiology, and clinical impact and current and upcoming therapeutic options of Pseudomonas aeruginosa, and describes future options, such as use of vaccines, antibodies, bacteriocins, anti-quorum sensing, and bacteriophages.
Journal ArticleDOI
New β-Lactam-β-Lactamase Inhibitor Combinations.
Dafna Yahav,Dafna Yahav,Christian G. Giske,Alise Grāmatniece,Alise Grāmatniece,Henrietta Abodakpi,Vincent H. Tam,Leonard Leibovici,Leonard Leibovici +8 more
TL;DR: These drugs provide various levels of in vitro coverage of carbapenem-resistant Enterobacterales, with several drugs presenting in vitro activity against MBLs (cefepime-zidebactam, aztreonam-avibactam., meropenem-nacubactam), and cefepim-taniborbactam).
Journal ArticleDOI
Treatment of Infections Due to MDR Gram-Negative Bacteria.
TL;DR: Treatment of severe MDR-GNB infections in critically ill patients in the near future will require an expert and complex clinical reasoning, of course taking into account the peculiar characteristics of the target population, but also the need for adequate empirical coverage and the more and more specific enzyme-level activity of novel antimicrobials with respect to the different resistance mechanisms.
Journal ArticleDOI
Ceftolozane–tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef,Martin Nováček,Ülo Kivistik,Álvaro Réa-Neto,Nobuaki Shime,Ignacio Martin-Loeches,Jean-François Timsit,Richard G. Wunderink,Christopher Bruno,Jennifer A. Huntington,Gina Lin,Brian Yu,Joan R. Butterton,Elizabeth G. Rhee +13 more
TL;DR: High-dose ceftolozane-tazobactam is an efficacious and well tolerated treatment for Gram-negative nosocomial pneumonia in mechanically ventilated patients, a high-risk, critically ill population.
References
More filters
Journal ArticleDOI
A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation☆
TL;DR: The method of classifying comorbidity provides a simple, readily applicable and valid method of estimating risk of death fromComorbid disease for use in longitudinal studies and further work in larger populations is still required to refine the approach.
Journal ArticleDOI
The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3)
Mervyn Singer,Clifford S. Deutschman,Christopher W. Seymour,Manu Shankar-Hari,Djillali Annane,Michael Bauer,Rinaldo Bellomo,Gordon R. Bernard,Jean-Daniel Chiche,Craig M. Coopersmith,Richard S. Hotchkiss,Mitchell M. Levy,John C. Marshall,Greg S. Martin,Steven M. Opal,Gordon D. Rubenfeld,Gordon D. Rubenfeld,Tom van der Poll,Jean Louis Vincent,Derek C. Angus +19 more
TL;DR: The task force concluded the term severe sepsis was redundant and updated definitions and clinical criteria should replace previous definitions, offer greater consistency for epidemiologic studies and clinical trials, and facilitate earlier recognition and more timely management of patients with sepsi or at risk of developing sepsic shock.
Journal ArticleDOI
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos,Arjun Srinivasan,R B Carey,Yehuda Carmeli,Matthew E. Falagas,Matthew E. Falagas,Christian G. Giske,Stéphan Juergen Harbarth,Janet F. Hindler,Gunnar Kahlmeter,Barbro Olsson-Liljequist,David L. Paterson,Louis B. Rice,John Stelling,Marc Struelens,Alkiviadis Vatopoulos,J T Weber,Dominique L Monnet +17 more
TL;DR: A group of international experts came together through a joint initiative by the European Centre for Disease Prevention and Control and the Centers for Disease Control and Prevention, to create a standardized international terminology with which to describe acquired resistance profiles in Staphylococcus aureus, Enterococcus spp.
Journal ArticleDOI
CDC definitions for nosocomial infections, 1988
TL;DR: The Centers for Disease Control (CDC) developed a new set of definitions for surveillance of nosocomial infections as mentioned in this paper, which combine specific clinical findings with results of laboratory and other tests that include recent advances in diagnostic technology.
Book
Performance standards for antimicrobial susceptibility testing
Melvin P. Weinstein,Clinical +1 more
TL;DR: The tabular information presented here represents the most current information for drug selection, interpretation, and QC using the procedures standardized in the most recent editions of M02, M07, and M11, and users should replace outdated editions with the current editions of CLSI documents.
Related Papers (5)
Effect and Safety of Meropenem–Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial
Richard G. Wunderink,Evangelos J. Giamarellos-Bourboulis,Galia Rahav,Amy J. Mathers,Matteo Bassetti,Jose A. Vazquez,Oliver A. Cornely,Joseph S. Solomkin,Tanaya Bhowmick,Jihad Bishara,George L. Daikos,Timothy Felton,Maria Jose Lopez Furst,Eun J. Kwak,Francesco Menichetti,Ilana Oren,Elizabeth Alexander,David E. Griffith,Olga Lomovskaya,Jeffery Loutit,Shu Zhang,Michael N. Dudley,Keith S Kaye +22 more
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A-P Magiorakos,Arjun Srinivasan,R B Carey,Yehuda Carmeli,Matthew E. Falagas,Matthew E. Falagas,Christian G. Giske,Stéphan Juergen Harbarth,Janet F. Hindler,Gunnar Kahlmeter,Barbro Olsson-Liljequist,David L. Paterson,Louis B. Rice,John Stelling,Marc Struelens,Alkiviadis Vatopoulos,J T Weber,Dominique L Monnet +17 more